Immediate Action Plan (Mild-Moderate Cases)

1 Subtype Assessment and Prioritized Treatment Planning

Before implementing the full intervention protocol, assess which subtype most closely matches your presentation. This guides resource allocation and helps prioritize which interventions to start first.

Recommendation: Subtype Classification for Mild-Moderate Patients

Rationale: Not all mild-moderate ME/CFS patients need identical treatment sequences. The selective energy dysfunction hypothesis (Section Selective Energy Dysfunction Hypothesis) proposes four subtypes with different treatment priorities.

Quick self-assessment:

What limits you MOST?
- Difficulty thinking, brain fog, concentration problems → CNS-Primary
- Dizziness standing, orthostatic symptoms, tachycardia → Autonomic-Primary
- Muscle weakness, fatigue, pain at rest → Peripheral-Primary
- Multiple systems equally affected → Global
Which systems are affected?
- Only cognition clearly impaired → Suggests CNS-Primary
- Only autonomic dysfunction prominent → Suggests Autonomic-Primary
- Only muscle/energy problems → Suggests Peripheral-Primary
- Three+ systems affected equally → Suggests Global

Treatment prioritization by subtype:

Subtype A (CNS-Primary):: Cognitive impairment dominates
- Priority 1: Cognitive support (neurotransmitter precursors—see Symptom Management)
- Priority 2: Sleep optimization (CNS recovery requires good sleep)
- Priority 3: Intranasal delivery for CNS compounds if available
Subtype B (Autonomic-Primary):: Orthostatic intolerance dominates
- Priority 1: Blood volume expansion (electrolytes, salt loading)
- Priority 2: Compression garments (see Orthostatic Intolerance section)
- Priority 3: Autonomic modulators (midodrine if prescribed)
Subtype C (Peripheral-Primary):: Muscle weakness/fatigue dominates
- Priority 1: Mitochondrial support (CoQ10, L-carnitine, D-ribose)
- Priority 2: Pain management (see Pain section)
- Priority 3: Gentle activity within envelope
Subtype D (Global):: Multi-system involvement
- Approach: Implement multi-domain protocol systematically
- Sequence: Start with sleep + pacing + electrolytes (foundational), then add domain-specific treatments week by week
- Integration: Watch for interactions between treatments; adjust pacing as interventions take effect

Evidence level: Plausible (subtype framework from Section Selective Energy Dysfunction Hypothesis); requires validation

Action: Identify your dominant subtype to guide prioritization, but do NOT delay foundational treatments (pacing, sleep, hydration) while waiting for subtype-specific optimization.

2 Core Principles

Prevent progression: Primary goal is to avoid worsening to severe ME/CFS
Optimize function: Maximize sustainable activity within energy envelope
Symptom control: Address limiting symptoms to improve quality of life
Root causes: Pursue disease-modifying treatments early, before exhaustion phase

3 Foundation: Energy Envelope Management

Critical Importance

Pacing is more important for mild-moderate cases than for severe cases, paradoxically. Severe patients are forced to rest by their symptoms. Mild-moderate patients can push through, leading to progressive worsening and eventual severity. The post-exertional malaise mechanism (Section Consequences of Energy Deficits) proposes that repeated energy envelope violations may cause cumulative mitochondrial damage and progressive decline—a model supported by indirect evidence from patient outcomes and cell biology but not yet confirmed by controlled longitudinal studies.

Key Point: Experimental: Emergency Post-Exertion Protocol for Unavoidable Situations

While pacing to avoid PEM remains the evidence-based gold standard, an experimental protocol exists for situations where exertion is truly unavoidable (medical emergencies, critical life events, accidental overexertion). This protocol targets the 24–72h cascade window with ATP substrates (D-ribose, citrulline-malate, MCT oil), NAD⁺ precursors (NR/NMN), glutathione support (NAC), and anti-inflammatory support to potentially reduce crash severity.

Evidence tier: Mechanistically justified but clinically unvalidated. No RCTs exist.

Key principle: Must address BOTH energy restoration (ATP/NAD⁺ support) AND inflammatory cascade interruption. Anti-inflammatories alone fail because ATP production failure is the root cause.

Appropriate use: True emergencies or unavoidable situations only—NOT routine use to enable chronic overexertion, which will cause progressive decline regardless of interventions.

See Chapter Emerging and Investigational Therapies, Emergency PEM Prevention Protocol for complete protocol, mechanistic rationale, and safety considerations. Also see Chapter Core Symptoms, Post-Exertional Malaise (PEM) for detailed discussion of why the 24–72h delay occurs and whether early intervention can prevent downstream cascade phases.

The Energy Envelope Concept

Available energy: Fixed daily energy budget (lower than healthy individuals)
Energy expenditure: All activities (physical, cognitive, emotional) cost energy
Energy envelope: Staying within available energy prevents PEM and progression
Exceeding envelope: Triggers PEM, depletes reserves, leads to progressive decline

Quantifying Your Envelope

Activity tracking (2-week baseline):
- Record all activities with duration and intensity
- Rate symptoms at end of each day (0–10 scale)
- Note PEM episodes (typically 24–72 hours post-exertion)
- Identify threshold: Maximum activity level that does NOT trigger PEM
Heart rate monitoring:
- Wear continuous HR monitor
- Calculate anaerobic threshold (AT): $(220 - \text{age}) \times 0.60$ for mild cases
- Optimal: Get CPET to measure actual AT
- Stay below AT for all activities
Symptom-based pacing:
- Stop activity BEFORE symptoms worsen
- If mild increase in fatigue/pain/brain fog → rest immediately
- Do not “push through”—this depletes reserves

Conservative Baseline Establishment During Interventions

Warning: Graded Exercise Therapy is Harmful

Graded exercise therapy (GET) has been heavily criticized for causing patient deterioration and is no longer recommended by major health organizations (National Institute for Health and Care Excellence 2021). The PACE trial, which originally promoted GET for ME/CFS, was subsequently discredited following reanalysis revealing unscientific methodology (Wilshire et al. 2018). Patient surveys document that 50–74% of ME/CFS patients report worsening from GET, including severe crashes, prolonged recovery periods, and permanent functional decline (Eaton-Fitch et al. 2019). Exercise “pushing through” symptoms violates the fundamental principle of energy envelope management and can trigger the post-exertional malaise mechanism. The “crash limit rule” from patient communities suggests individuals should not experience more than 5 total severe crashes, as recovery time increases with each subsequent crash, potentially leading to irreversible worsening.

Warning: Do Not Test PEM During Early Intervention Phase

When starting new interventions (electrolytes, supplements, medications), resist the urge to “test” whether you can now do more activity. Initial improvements may reflect temporary metabolic support rather than restored capacity.

Critical principles:

Establish baseline stability first: Minimum 2–4 weeks of consistent symptom improvement before considering activity increase
PEM can occur without identifiable trigger: Even “normal” daily activities (childcare, sitting at computer) may trigger crashes when operating near threshold
Afternoon crash patterns persist: Metabolic improvements may reduce crash severity but vulnerability windows remain
Joint pain as inflammatory marker: Severe joint pain during crashes indicates cytokine/inflammatory component; pain resolution with magnesium does not eliminate crash risk

Why this matters:

Electrolyte/supplement improvements address symptoms and metabolic bottlenecks
Underlying PEM mechanism (Section Consequences of Energy Deficits) remains active
Testing limits during early intervention phase can trigger severe crashes that erase weeks of progress
Example: Patient improving on day 3 of electrolyte protocol wisely stated “PEM: not tested yet, I don’t dare” — this caution prevented potential severe relapse

Appropriate timeline for activity testing:

Weeks 1–4: Establish intervention (electrolytes, supplements, medications); maintain current activity level
Weeks 4–8: If stable improvement sustained, very gradually test small increases (5–10% activity increase)
Months 2–3: If no PEM episodes, consider slightly larger envelope expansion
Always: If any PEM episode occurs, immediately return to prior safe activity level

50% Rule for Mild-Moderate Cases

Conservative estimate: Do 50% of what you think you can do
Example: If you feel you can walk 30 minutes, walk 15 minutes
Example: If you feel you can work 8 hours, work 4 hours
Rationale: Most patients overestimate capacity; 50% rule provides safety margin
Adjustment: If no PEM after 2 weeks at 50%, increase to 60%; iterate until you find sustainable level

Preventing Boom-Bust Cycles

Boom phase: Feel better → do too much → crash
Bust phase: Severe PEM → bedbound → recover slowly → repeat
Solution: Consistent daily activity within envelope, even on “good days”
Good days: Do NOT increase activity; bank energy for inevitable bad days

3.1 Energy Triage: Cognitive Task Hierarchy-Aware Activity Planning

The selective energy dysfunction hypothesis (Section Selective Energy Dysfunction Hypothesis) proposes that the CNS implements a hardwired energy allocation hierarchy under scarcity, with complex cognition (Tier 6) sacrificed first, while sensory and motor functions (Tier 2–3) are preserved longer.

Key Point: Energy Triage Hierarchy: From Selective Dysfunction Framework

Tier 1 (never sacrificed): Brainstem vital functions
Tier 2: Sensory processing
Tier 3: Motor coordination
Tier 4: Memory consolidation
Tier 5: Executive function
Tier 6 (first sacrificed): Complex cognition

Key insight: When energy is limited, Tier 6 (abstract reasoning, creative work, complex decision-making) fails first. Tier 2–3 (sensory processing, basic movement) remain functional longer. This means you can sustain simple physical or sensory activities that would be impossible if they required executive function.

Recommendation: Cognitive Hierarchy-Aware Task Allocation Strategy

Mechanism: Schedule cognitively demanding tasks (Tier 5–6) during peak energy only; shift to simpler tasks (Tier 2–3) when fatigued. This preserves cognitive function for priorities while allowing continued engagement with less demanding activities. See Section Selective Energy Dysfunction Hypothesis for the CNS energy triage hypothesis.

Practical implementation:

Identify your peak energy window (typically morning): This is when you have maximum CNS energy for Tier 5–6 tasks
Schedule by tier priority:
- Peak energy block (60–90 minutes): Executive function tasks (planning, decision-making, creative work, complex learning)
- Mid-energy block (1–2 hours): Memory/attention-demanding tasks (reading complex material, detailed work)
- Lower-energy blocks: Tier 2–3 tasks (listening to audiobooks, simple crafts, organizing, light physical activity, socializing)
- Fatigue phase: Tier 1–2 only (rest, basic self-care, passive activities)
Avoid tier-switching costs: Switching between high-tier and low-tier tasks wastes cognitive energy. Instead:
- Complete all Tier 6 tasks first
- Then all Tier 5 tasks
- Then progressively simpler tiers as energy declines
- Do NOT alternate (e.g., complex work → audiobook → more complex work)
Examples of task mapping:
- Tier 6 (complex cognition): Strategic planning, problem-solving, learning new concepts, creative writing
- Tier 5 (executive function): Email management, appointment scheduling, decision-making, multitasking
- Tier 4 (memory): Reading familiar topics, following detailed instructions, recalling information
- Tier 3 (motor): Gentle exercise, cooking simple meals, organizing objects, simple crafts
- Tier 2 (sensory): Listening to music/audiobooks, watching shows, passive observation
- Tier 1 (vital): Breathing, resting, basic autonomic functions

Evidence level: Plausible (formal triage model from Section Selective Energy Dysfunction Hypothesis; clinical validation pending)

Expected benefit: By aligning task demands with available energy across the day, you can:(1) Complete important cognitive tasks during peak windows, preventing decision fatigue; (2) Maintain some activity during lower-energy periods without requiring cognitive effort; (3) Reduce overall symptom burden through better energy allocation.

3.2 Crash Severity Dose-Response: Why Large Violations Are Catastrophic

Not all energy envelope violations are equally harmful. Emerging evidence and patient experience suggest a dose-response relationship between exertion magnitude and crash severity, with critical thresholds beyond which damage becomes irreversible.

The Threshold Hypothesis.

Hypothesis: Crash Severity Dose-Response

Certainty: 0.30. Small envelope violations (110–120% of safe capacity) produce reversible crashes with full recovery in days to weeks. Moderate violations (150–180%) cause extended recovery (weeks to months) but may still be reversible with aggressive rest. Large violations ($>$ 200% capacity) cause irreversible damage, permanent worsening, and engagement of ratchet effect mechanisms (see Chapter Core Symptoms, Post-Exertional Malaise (PEM), “Ratchet Effect”). This hypothesis extrapolates from general cell biology thresholds; no ME/CFS-specific dose-response data exist.

Mechanistic basis:

ATP depletion threshold: Cells can tolerate 20–30% ATP depletion and recover; depletion $>$ 50–70% triggers apoptosis or permanent mitochondrial damage (Heng et al. 2025)
Mitochondrial turnover capacity: Based on general principles of mitochondrial biology, mild mitochondrial damage may be cleared by mitophagy within days; massive, widespread damage could overwhelm biogenesis capacity and leave permanent deficits (specific thresholds in ME/CFS not yet established empirically)
Inflammatory cascade intensity: Small acute immune activation typically self-limits within days; severe or persistent cytokine elevation may trigger autoimmune cascades or chronic microglial priming (extrapolated from neuroinflammation literature (Nakatomi et al. 2014))
Epigenetic locking: Extreme cellular stress may trigger permanent epigenetic changes (DNA methylation, histone modification) that maintain dysfunction even after stressor resolves (Lawless et al. 2015)

Clinical implication: Preventing ALL large crashes is more important than preventing frequent small crashes. One catastrophic crash may cause more permanent damage than ten minor crashes.

Crash Severity Classification System.

To operationalize crash prevention, we propose a four-tier severity classification:

Crash Severity Classification with Dose-Response Predictions
Tier	Exertion Relative to Envelope	Typical Recovery Time	Predicted Long-Term Impact	Minor
110–130% of safe capacity	2–7 days	Fully reversible; no permanent damage if infrequent ($<$ 1/month)	Moderate	150–180% of safe capacity
1–4 weeks	Reversible with aggressive rest; may slightly lower baseline if frequent ($>$ 2/month)	Severe	200–300% of safe capacity	1–3 months
Partially reversible; likely permanent 5–15% function loss; accelerates progression	Catastrophic	$>$ 300% of safe capacity	3–12+ months, or never	Irreversible; permanent 20–50% function loss; triggers Stage N$\rightarrow$N+1 cycle entry

{Note: Percentages are illustrative estimates based on patient reports and PEM mechanism; no controlled studies exist. “Safe capacity” = maximum activity level that does NOT trigger PEM. Example: If safe walking distance is 1000 steps/day, Minor = 1100–1300 steps, Moderate = 1500–1800 steps, Severe = 2000–3000 steps, Catastrophic = $>$ 3000 steps.}

Evidence Supporting Dose-Response.

While no formal studies have tested the crash severity dose-response hypothesis, multiple lines of evidence support it:

Patient retrospective analysis: Community surveys consistently identify specific “life-changing crashes” after which patients never returned to baseline
- Common triggers: attempting to return to work full-time after diagnosis, major life events (weddings, moving house), exercise programs (GET, personal training)
- Pattern: Massive exertion → severe crash → permanent 20–50% function loss
- Contrast: Patients who avoid catastrophic crashes may slowly improve or stabilize; those with 1–2 catastrophic crashes often progress to severe disease
Recovery kinetics: Exponentially longer recovery from larger crashes suggests threshold crossing
- Minor crash: 2–7 days (proportional to exertion)
- Catastrophic crash: 6–12 months (disproportionate to exertion magnitude)
- Non-linearity suggests biological threshold (ATP depletion, cell death) was crossed
Two-day CPET as controlled crash: Standardized exertion to ventilatory threshold
- Day 2 testing triggers moderate-to-severe crash in most ME/CFS patients
- Recovery time averages 13 days but ranges 7–60+ days (Keller et al. 2024)
- Patients with longer recovery ($>$ 30 days) may have crossed threshold into irreversible damage
Mitochondrial damage-repair dynamics: Basic biology supports threshold model
- Mitochondrial biogenesis capacity: $\sim$ 10–15%/day of total mitochondrial mass
- If $>$ 40–50% of mitochondria damaged simultaneously, replacement takes weeks; during this time, cells operate at massive ATP deficit
- Prolonged severe ATP deficit may trigger cell death (particularly neurons, which cannot regenerate)

Informal Patient Observation: “Crash Limit Rule.” Patient communities have reported an informal pattern suggesting cumulative worsening with repeated severe crashes, sometimes called the “crash limit rule.” No systematic study has quantified crash thresholds, and the specific numbers circulating in patient communities (e.g., 5 severe crashes, 2-week to 6-month recovery progression) have no empirical basis—they should not be treated as clinical cutoffs. The qualitative pattern of progressively impaired recovery with repeated severe crashes is, however, consistent with the mitochondrial and epigenetic mechanisms described below.

Mechanistic Basis: Why Thresholds Exist.

Four converging biological mechanisms explain why crash consequences become catastrophic beyond specific exertion thresholds:

ATP Depletion Thresholds: Normal cellular function requires ATP maintained at 50–80% of maximum capacity. Mild exertion depletes ATP to 40–50% (reversible in hours). At 30–50% depletion, AMPK stress pathways activate; at $>$ 50% depletion, mitochondrial permeability transition (mPT) occurs with irreversible damage; at $>$ 70% depletion, apoptotic signaling triggers cell death. In ME/CFS, impaired ATP production means even moderate exertion may cross the 50% threshold.
Mitochondrial Turnover Limits: Biogenesis operates at 10–15%/day under optimal conditions. If $<$ 30% of mitochondria are damaged, clearance occurs in 2–7 days. If 30–50% are damaged, recovery requires 3–5 weeks with prolonged severe ATP deficit. If $>$ 50% are damaged, regeneration capacity is overwhelmed, resulting in permanent mitochondrial density reduction.
Inflammatory Cascade Intensity: Post-exertional cytokine release follows dose-response kinetics. Mild exertion triggers 2–3-fold cytokine elevation, resolving in 2–3 days. Severe exertion may trigger $>$ 10-fold elevation, causing microglial priming (brain), endothelial dysfunction (blood vessels), and fibrotic signaling. Once primed, microglia remain hyperreactive for months to years.
Epigenetic Locking: Severe cellular stress triggers DNA methylation and histone modifications. Under normal stress, these reverse when stress resolves. Under extreme stress ($>$ 200% capacity), changes may lock: hypermethylation of biogenesis genes (PGC-1$\alpha$, TFAM) permanently reduces mitochondrial regeneration capacity; inflammatory promoter modifications maintain chronic low-grade inflammation.

Convergent threshold model: Below capacity, cells cope and recover. At 130–150% capacity, one or two mechanisms trigger. At $>$ 200% capacity, all four mechanisms activate simultaneously, creating a cascade of irreversible damage: severe ATP depletion → apoptosis → DAMP release → amplified inflammation → damaged remaining mitochondria → regeneration overwhelmed → epigenetic locking. This explains the clinical observation that catastrophic crashes cause disproportionate, irreversible harm.

Clinical Crash Prevention Strategy.

The dose-response model generates specific clinical guidance:

Key Point: Asymmetric Crash Prevention: Severe $>$ Frequent

Priority 1: Prevent ALL catastrophic and severe crashes (Tiers 3–4)

These cause irreversible damage; even one catastrophic crash may permanently worsen disease
Justifies extreme caution: cancel essential appointments, use wheelchair, accept help, disappoint others
Example: Patient facing unavoidable high-exertion event (wedding, funeral, medical procedure) → use Emergency PEM Prevention Protocol (Chapter Emerging and Investigational Therapies, Practical Warning) + pre-rest for 3–5 days + post-rest for 7–14 days

Priority 2: Minimize moderate crashes (Tier 2)

Occasional moderate crashes may be tolerable (1–2/year for special events)
Frequent moderate crashes ($>$ 1/month) likely cause slow progression
Example: Patient wants to attend important family event → plan meticulously, rest before/after, accept crash will occur but keep it moderate (not severe)

Priority 3: Tolerate occasional minor crashes (Tier 1)

Minor crashes may be unavoidable in daily life (illness, stress, unexpected demands)
Fully reversible if infrequent; do not obsess over perfection
Example: Unplanned phone call, minor errand, child needs attention → brief minor crash acceptable, recover within week

Key principle: It is better to have 10 minor crashes per year than 1 catastrophic crash. Damage is non-linear; severe crashes disproportionately drive progression.

Identifying Your Crash Threshold.

Since individual capacity varies enormously (bedbound patients: 100 steps = catastrophic; mild patients: 5000 steps = moderate), each patient must identify their personal thresholds:

Establish baseline safe capacity: 2–4 weeks activity tracking; find maximum activity causing NO PEM
Define crash tiers relative to baseline:
- Minor: 110–130% of baseline (e.g., 1100–1300 steps if baseline is 1000)
- Moderate: 150–180% of baseline (1500–1800 steps)
- Severe: 200–300% of baseline (2000–3000 steps)
- Catastrophic: $>$ 300% of baseline ($>$ 3000 steps)
Track crash history: Note which activities triggered which tier crashes; identify patterns
Adjust safety margin: If even “safe” activities occasionally cause crashes, reduce baseline by 10–20%

Emergency Crash Management Protocol.

If a severe or catastrophic crash occurs despite prevention efforts:

Warning: Severe Crash = Medical Emergency

Treat severe/catastrophic crashes as medical emergencies requiring immediate aggressive intervention:

Immediate actions (0–6 hours post-crash):

Complete cessation of ALL activity: Horizontal rest, minimal stimulation, no cognitive demands
Emergency metabolic support: D-ribose 15 g, MCT oil 30 mL, NAD⁺ precursor 1000–2000 mg, high-dose antioxidants (see Emergency PEM Protocol, Chapter Emerging and Investigational Therapies, Practical Warning). Note: these supplements are mechanistically motivated but lack controlled trial evidence for acute PEM management; efficacy is based on patient reports and biological plausibility
Hydration + electrolytes: 500 mL oral rehydration solution every 2–3 hours
Anti-inflammatory support: Omega-3 4 g, curcumin 1000 mg, consider NSAIDs if no contraindications
Sleep optimization: Prioritize 10–12 hours sleep; melatonin 1–3 mg, magnesium 400 mg

Extended recovery phase (Days 1–14):

Strict rest enforcement: No work, no errands, minimal self-care only
Continued metabolic support: D-ribose 5 g TID, NAD⁺ precursors 500 mg BID, antioxidants, anti-inflammatories
Monitor for secondary complications: Orthostatic worsening, new pain, cognitive decline; treat symptomatically
Resist activity resumption: Even if feeling better at Day 7–10, maintain rest through Day 14 minimum

Gradual return (Weeks 3–8):

Resume at 25–50% of pre-crash baseline: Do NOT return to pre-crash activity level
Re-establish new safe baseline: May be permanently lower; accept functional loss
Monitor for delayed secondary crash: Weeks 3–4 carry high risk; maintain caution
Medical consultation: If no improvement by Week 8, consider aggressive interventions (see Chapter Urgent Action Plan for Severe Cases)

Reality: Despite optimal management, catastrophic crashes may cause permanent 20–50% function loss. This is why prevention is absolute priority.

Research Directions: Validating Dose-Response.

To test the crash severity dose-response hypothesis:

Retrospective cohort analysis: Survey ME/CFS patients about lifetime crash history
- Correlate number of severe/catastrophic crashes with current disease severity
- Hypothesis: Patients with $\geq$ 3 catastrophic crashes are 5–10$\\times$ more likely to be severe/very severe
- Confounders: Crash severity may correlate with baseline disease severity (sicker patients crash more easily)
Prospective biomarker study: Standardized exertion at multiple intensities
- Mild exertion (50% AT), moderate (75% AT), maximal (100% AT, CPET)
- Serial biomarkers: ATP/ADP, lactate, cytokines, oxidative stress markers at 0h, 6h, 24h, 48h, 72h post-exertion
- Hypothesis: Biomarker perturbations are non-linear; doubling exertion intensity causes 5–10$\\times$ biomarker changes
- Identify thresholds where reversible dysfunction becomes irreversible damage
Natural history tracking with wearables: 100+ ME/CFS patients wearing continuous activity monitors for 1–2 years
- Correlate crash magnitude (actigraphy-derived) with recovery duration
- Identify if specific crashes preceded permanent functional decline
- Machine learning to predict “dangerous” activity patterns
Intervention trial: Emergency PEM Protocol vs placebo after standardized severe exertion
- Outcome: Does aggressive post-exertion support reduce irreversible damage?
- Measure function at 6 months post-crash; hypothesis: intervention prevents permanent worsening

Key Point: Crash Prevention as Disease-Modifying Therapy

If the dose-response hypothesis is correct, aggressive crash prevention is not merely symptom management—it is disease-modifying therapy. Preventing 1–2 catastrophic crashes may prevent progression from mild to severe disease, preserving decades of quality-adjusted life-years.

This elevates pacing from “lifestyle adjustment” to primary medical intervention with potentially greater impact than any pharmaceutical.

The challenge: Crash prevention requires life disruption, social sacrifice, and accepting severe limitations. Patients face pressure to “try harder,” attend events, maintain employment. Clinicians must validate that extreme caution is medically justified—not psychological avoidance—and that preventing catastrophic crashes is worth the social and economic costs.

3.3 Advanced Pacing Approaches

Standard energy envelope management relies on subjective symptom monitoring and retrospective crash analysis. Two emerging approaches offer more objective, proactive guidance: HRV-guided activity management and periodized activity cycling adapted from sports medicine.

Protocol: HRV-Guided Activity Management

Heart rate variability (HRV) provides an objective window into autonomic nervous system recovery status. This protocol uses daily HRV measurement to determine activity budgets, potentially preventing crashes before they occur.

Physiological Basis HRV reflects the balance between sympathetic and parasympathetic nervous system activity. High HRV (particularly high-frequency power, reflecting parasympathetic tone) indicates a recovered, resilient autonomic system. Low HRV indicates stress, incomplete recovery, or autonomic dysregulation. In athletes, low morning HRV predicts poor training tolerance and increased injury risk (Plews et al. 2013). The same principle may apply to ME/CFS activity tolerance.

Measurement Protocol

Timing: Immediately upon waking, before getting out of bed
Duration: 3–5 minute recording
Position: Supine, relaxed breathing
Metrics: RMSSD (root mean square of successive differences) or HF power
Baseline establishment: 14 days of daily measurement to establish personal baseline; calculate 7-day rolling average

Validated Devices

Chest strap monitors: Polar H10, Garmin HRM-Pro (gold standard accuracy)
Wrist-based: Oura Ring (validated for overnight HRV), Whoop, Garmin watches (acceptable accuracy for trends)
Apps: Elite HRV, HRV4Training (provide analysis algorithms; require compatible sensor)

Activity Calibration

HRV $>$ 105% of baseline: Green day—normal activity budget allowed
HRV 90–105% of baseline: Yellow day—reduce planned activity by 20%; increase rest periods
HRV 75–90% of baseline: Orange day—reduce activity by 40%; prioritize rest; cancel optional commitments
HRV $<$ 75% of baseline: Red day—minimal activity only; active recovery day; cancel all non-essential activities

Integration with Activity Planning

Check HRV before committing to activities
Reschedule appointments when HRV indicates poor recovery state
Use HRV as “training wheels” for learning to recognize internal recovery signals
Over time, patients may develop interoceptive awareness that correlates with HRV readings

Evidence Status HRV-guided training is well-established in sports science (Plews et al. 2013) (Addleman et al. 2024), with consistent evidence that reduced HRV predicts poor training tolerance and overtraining syndrome (Meeusen et al. 2013). Preliminary evidence supports HRV’s utility in ME/CFS: Escorihuela et al. (Escorihuela et al. 2020) demonstrated that reduced HRV predicts fatigue severity in ME/CFS patients (n=45), with RMSSD, mean RR intervals, and high-frequency power all significantly correlating with self-reported fatigue (p < 0.03). This suggests HRV may serve as an objective indicator of physiological reserve.

However, individual variation in HRV response is substantial; the protocol requires personalization. Some ME/CFS patients have chronically suppressed HRV, requiring adjusted thresholds. Consumer wearable devices are evolving rapidly but require validation for clinical use (K. Li et al. 2023). A proposed RCT comparing HRV-guided to standard pacing is described in Chapter Entries added 2026-08-26: Central Motor-Drive Fatigability Cascade (Bedard 2026), Section HRV-Guided Pacing Randomized Controlled Trial.

Protocol: Periodized Activity Cycling

Certainty: 0.30. Periodized activity cycling (alternating planned deload and maintenance phases) adapted from sports medicine may optimize recovery compared to static activity maintenance in ME/CFS. The certainty level reflects: (1) well-established efficacy of periodization in athletic training for preventing overtraining syndrome; (2) theoretical parallel between overtraining and ME/CFS post-exertional malaise; (3) however, lack of any randomized controlled trials directly testing periodization in ME/CFS; (4) inability to replicate the controlled training environments of sports medicine in heterogeneous ME/CFS populations; (5) fundamental uncertainty about whether the overtraining syndrome model accurately describes ME/CFS physiology; (6) high inter-individual variation in activity tolerance that may render standardized cycles ineffective.

Standard ME/CFS pacing emphasizes maintaining a constant activity level within the energy envelope. An alternative approach, adapted from sports medicine management of overtraining syndrome, employs structured cycles of rest and activity that may better support recovery than static management.

Cross-Domain Insight Overtraining syndrome (OTS) in athletes shares features with ME/CFS: persistent fatigue, performance decline, sleep disturbance, mood changes, and autonomic dysfunction (Meeusen et al. 2013). However, OTS outcomes are substantially better—most athletes recover within weeks to months with structured rest-activity cycles. While OTS and ME/CFS likely have different underlying pathophysiology, the recovery principles may be partially transferable.

Key Difference from Standard Pacing Standard pacing maintains constant activity at 50–80% of the energy envelope indefinitely. Periodized cycling alternates between:

Deload phases: Reduced activity below the usual envelope, allowing deeper recovery
Maintenance phases: Standard envelope activity
Probe phases: Carefully monitored slight increases to test capacity (only if stable)

Example 8-Week Cycle

Weeks 1–2 (Deload): 30–50% of usual activity; prioritize sleep extension (10+ hours if possible); anti-inflammatory nutrition emphasis; cancel all optional activities
Weeks 3–4 (Recovery): 60–70% of usual activity; maintain extended sleep; continue anti-inflammatory support
Weeks 5–6 (Maintenance): Return to usual sustainable activity level (70–80% envelope); monitor HRV for stability
Weeks 7–8 (Probe—if stable): Very slight activity increase (5–10%); immediate reduction if any warning signs; if tolerated, this becomes new maintenance level
Repeat cycle

Adjunctive Elements

HRV monitoring: Required throughout; cycle timing should align with HRV patterns
Recovery nutrition: Increased anti-inflammatory foods during deload; protein for tissue repair
Sleep extension: Particularly during deload phases; aim for 9–10 hours
Stress minimization: Schedule demanding life events (appointments, social obligations) during maintenance phases, not deload

Cautions and Contraindications

Not for severe patients: Periodization assumes capacity for activity variation; very severe patients may not tolerate even deload-level activity
PEM monitoring essential: Any PEM during probe phases requires immediate return to deload
Individual cycle length: 8 weeks is illustrative; some patients may need 12-week or 6-week cycles based on their recovery kinetics
Experimental approach: No RCT evidence exists comparing periodized to standard pacing in ME/CFS

Distinction from GET Periodized activity cycling is fundamentally different from graded exercise therapy (GET):

GET assumes patients can progressively increase activity indefinitely—periodization includes mandatory deload phases
GET ignores PEM signals—periodization treats any PEM as immediate stop signal
GET aims to “decondition” patients from activity avoidance—periodization respects energy envelope as biological reality
GET was designed for presumed psychological aversion—periodization is designed for physiological recovery optimization

3.4 Sports Medicine Deload Principles

The periodized activity cycling protocol (Protocol Periodized Activity Cycling) draws from sports medicine principles of structured recovery. Recent consensus work in athletic training provides more detailed guidance on deload implementation that may inform ME/CFS pacing strategies.

Deload Definition and Rationale

Bell et al. (Bell et al. 2023) define deloading in athletic contexts as “a period of reduced training stress designed to mitigate physiological and psychological fatigue, promote recovery, and enhance preparedness for subsequent training” (n=34 expert coaches, Delphi consensus). In athletes, deloads prevent cumulative fatigue that would otherwise lead to overtraining syndrome. The parallel to ME/CFS: regular planned reductions in activity may prevent the accumulation of metabolic and immune stress that precipitates crashes.

Evidence-Based Parameters from Athletic Training

Sports science research establishes:

Frequency: Deloads every 4–6 weeks in athletic populations (Bell et al. 2023)
Duration: Approximately 7 days (range: 3–14 days depending on individual response)
Volume reduction: 40–60% reduction in total activity through fewer “sets” (activity bouts), shorter duration, or reduced frequency
Intensity: May remain moderate while volume decreases, OR both reduced together
Implementation: Pre-planned (calendar-based) or autoregulatory (HRV/symptom-driven)

Adaptation for ME/CFS: Critical Differences

Direct application of athletic deload protocols to ME/CFS would be inappropriate. Key adaptations required:

Baseline capacity: Athletes start from high-normal fitness; ME/CFS patients from 10–20% of healthy capacity. Activity “volume” in ME/CFS refers to activities of daily living (cooking, hygiene, short walks), not structured training.
Recovery timelines: Athletes recover from deconditioning in weeks; ME/CFS recovery (if it occurs) requires months to years. Athletic 7-day deloads become 7–14 day deloads in ME/CFS.
Progression philosophy: Athletic training aims for continuous improvement; ME/CFS management prioritizes stability and preventing deterioration. Any capacity increases are secondary goals.
Consequence of error: Athletes who overtrain risk temporary performance setbacks; ME/CFS patients who exceed energy envelope risk prolonged relapse. The stakes are fundamentally different.

Warning: Not for Severe or Very Severe Patients

Sports medicine-adapted protocols assume the patient can engage in some level of activity variation and monitoring. Severe and very severe ME/CFS patients who are bedbound or housebound should not attempt structured deload cycling. For these patients, standard pacing with minimization of all non-essential activity remains the evidence-based approach.

Who May Benefit: Selection Criteria

Sports medicine-adapted pacing may be appropriate for:

Mild to moderate ME/CFS patients (ambulatory, able to perform some daily activities)
Stable baseline established over 4+ weeks (no recent crashes)
Previous athletic background (familiar with structured training concepts)
Comfort with quantitative tracking and data collection
Access to monitoring tools (smartphone, wearables, tracking apps)
Psychological readiness for disciplined, patient approach
Understanding that “progressive overload” is NOT “push through pain”

Contraindications:

Severe or very severe ME/CFS
Actively deteriorating or unstable condition
Recent major crash (within 3 months)
Tendency toward overachievement or ignoring warning signals
Psychological distress from metrics or self-monitoring

3.5 Objective Recovery Monitoring Beyond HRV

While HRV provides sophisticated autonomic assessment (Protocol HRV-Guided Activity Management), simpler metrics may complement or substitute when HRV monitoring is impractical.

Resting Heart Rate (RHR) as Recovery Indicator

Resting heart rate offers a zero-cost alternative to HRV for tracking recovery status:

Protocol: Resting Heart Rate Monitoring

Measurement Protocol:

Measure immediately upon waking, before getting out of bed
Use manual palpation (radial or carotid pulse for 60 seconds) or wearable device
Record daily for 14 days to establish personal baseline
Calculate 7-day rolling average

Interpretation:

RHR within 3 bpm of baseline: Normal recovery state; proceed with planned activities
RHR 4–6 bpm above baseline: Caution—reduce activity by 20–30%; monitor closely
RHR 7+ bpm above baseline: Red flag—significant incomplete recovery; reduce activity by 50%; consider early deload phase
Sustained elevation (3+ days): Strong signal for deload cycle regardless of calendar schedule

Evidence Base: Sports medicine literature consistently identifies 5–7 bpm RHR elevation as indicating incomplete recovery or overtraining risk in athletes. However, individual variation is substantial; personal baseline comparison is more meaningful than absolute values. RHR is less sensitive than HRV but far more accessible.

Limitations:

Affected by sleep quality, hydration, ambient temperature, illness
Less sensitive than HRV to subtle autonomic changes
ME/CFS patients may have dysautonomia causing chronically elevated RHR; focus on trends and relative changes

Combined Monitoring Strategy

For maximal sensitivity, combine multiple metrics:

Primary: HRV (if available and validated device)
Secondary: Resting heart rate (accessible to all)
Tertiary: Subjective recovery scales (see below)
Integration rule: Use most conservative signal; if any metric indicates poor recovery, reduce activity regardless of other metrics

3.6 Subjective Recovery Scales

Systematic reviews of athletic monitoring demonstrate that subjective self-report measures often outperform objective physiological markers for detecting overtraining (Hooper and Mackinnon 1995). Structured subjective scales may enhance ME/CFS self-monitoring.

Recovery-Stress Assessment

Validated tools from sports science include:

Profile of Mood States (POMS): Tracks tension, depression, anger, fatigue, confusion, vigor
Recovery-Stress Questionnaire for Athletes (RESTQ-Sport): 76-item assessment of recovery and stress states
Daily Analyses of Life Demands (DALDA): Simple daily symptom checklist
Acute Recovery and Stress Scale (ARSS): Recently validated brief scale for daily use

For ME/CFS, complex questionnaires may create excessive burden. A simplified approach:

Protocol: Daily Recovery Self-Rating

Each morning, rate recovery status on 0–10 scale:

0–2: Severely unrecovered; significant symptom burden; minimal functional capacity
3–4: Poor recovery; moderate symptoms; reduced capacity
5–6: Moderate recovery; mild symptoms; functional but limited
7–8: Good recovery; minimal symptoms; near-normal capacity for individual
9–10: Excellent recovery; no or trivial symptoms; optimal function

Additional Quick Ratings (0–10 scale):

Sleep quality (0=terrible, 10=excellent)
Cognitive clarity (0=severe brain fog, 10=clear thinking)
Physical energy (0=exhausted, 10=energetic)
Pain level (0=no pain, 10=severe pain)
Stress level (0=calm, 10=highly stressed)

Use of Data:

Track weekly average and trend
If weekly average declining over 2 weeks: initiate deload regardless of calendar
If recovery rating <5 for 3+ consecutive days: reduce activity immediately
Use in combination with objective metrics (HRV, RHR) for comprehensive picture

3.7 Practical Implementation Framework

For patients considering sports medicine-adapted pacing, a phased implementation reduces risk:

Phase 1: Baseline and Monitoring Setup (Weeks 1–4)

Establish stable activity baseline (no increases; just observe current capacity)
Implement daily monitoring: RHR, subjective recovery rating, sleep quality
Optional: Add HRV if device available
Track PEM occurrences (frequency, severity, triggers)
Calculate personal baseline for all metrics
Goal: 4 weeks of stable data before any changes

Phase 2: First Planned Deload (Week 5)

Reduce activity to 50% of baseline week
Focus on rest, sleep extension (aim for 9–10 hours), gentle movement only
Continue all monitoring
Observe: Do recovery metrics improve during deload? By how much?
If no improvement or worsening: standard pacing may be more appropriate than periodization

Phase 3: Return to Baseline (Weeks 6–7)

Gradually return to pre-deload baseline activity level
Monitor for PEM or metric deterioration
If stable: baseline re-established
If unstable: remain at reduced level; reconsider approach

Phase 4: Assessment and Decision (Week 8)

Review 8-week data: trends in RHR, HRV, subjective ratings, PEM frequency
If improving: Consider continuing with 4–6 week cycles
If stable: Continue cycles with no progression attempts; cycles maintain stability
If declining: Return to standard flexible pacing; periodization may not suit individual physiology

Long-Term Management

Deload every 4–6 weeks (pre-planned) OR when metrics indicate (autoregulatory)
Never attempt progression if unstable
If stable for 3+ months: may consider ultra-conservative 5% activity increase; immediate rollback if any PEM
Reassess approach every 3–6 months; be willing to abandon if not beneficial

Recommendation: Physician Consultation

Patients attempting structured periodization should discuss the approach with their ME/CFS-knowledgeable physician. Monitoring data (RHR trends, recovery ratings, PEM logs) should be shared at appointments to enable collaborative adjustment. Any worsening of baseline function requires immediate return to standard pacing and medical evaluation.

Critical Distinction: This Is Not GET

Sports medicine-adapted pacing shares superficial similarities with graded exercise therapy (GET) but differs fundamentally in philosophy and implementation:

Comparison of GET vs. Sports Medicine-Adapted Pacing
GET (Inappropriate for ME/CFS)	Sports-Adapted Pacing	Assumes progressive increase indefinitely	Includes mandatory regular deloads	Treats PEM as psychological barrier to overcome
Treats PEM as hard biological stop signal	Fixed progression schedule regardless of symptoms	Autoregulatory adjustment based on recovery metrics	Aims to “decondition” from activity avoidance	Respects energy envelope as physiological reality
Based on deconditioning hypothesis	Based on metabolic/immune recovery optimization	Ignores autonomic dysfunction	Incorporates HRV/RHR monitoring	One-size-fits-all protocol
Highly individualized to patient metrics	Progression is primary goal	Stability is primary goal; progression secondary if at all

The distinction is critical: GET has been shown to be harmful in significant subsets of ME/CFS patients (Eaton-Fitch et al. 2019) (Wilshire et al. 2018) and is no longer recommended by CDC, NIH, or major ME/CFS specialist organizations (National Institute for Health and Care Excellence 2021). Sports-adapted pacing, by contrast, is explicitly designed around energy envelope theory and includes structured recovery phases. However, it remains an experimental approach without ME/CFS-specific validation and must be implemented with extreme caution.

Evidence Status

Certainty Assessment:

Athletic deload protocols: High-quality evidence in sports science
OTS parallels to ME/CFS: Medium-quality observational evidence; significant differences exist
HRV and RHR monitoring: High-quality in athletes; limited data in ME/CFS
ME/CFS adaptation: Low-quality; theoretical extrapolation only; no RCTs

Open Question: Sports-Adapted Pacing: Unresolved Evidence Gaps

Randomized controlled trials comparing sports-adapted versus standard pacing in ME/CFS do not yet exist. Specifically unresolved: optimal deload frequency, duration, and depth; long-term outcomes beyond 6 months; validated patient selection criteria; and systematic safety evaluation.

Proposed Research: Chapter Entries added 2026-08-26: Central Motor-Drive Fatigability Cascade (Bedard 2026) includes a proposal for an RCT comparing sports medicine-adapted periodization to standard flexible pacing in mild-moderate ME/CFS (Section Sports Medicine-Adapted Periodization RCT).

Clinical Bottom Line

Sports medicine-adapted pacing represents a reasonable experimental approach for carefully selected mild-moderate ME/CFS patients who:

Have stable baselines
Are comfortable with structured monitoring
Understand the distinction from GET
Accept the lack of ME/CFS-specific validation
Are willing to abandon the approach if unhelpful or harmful

It should be implemented conservatively, with close monitoring, and under physician guidance. Standard flexible pacing remains the evidence-based default for all patients, particularly those with severe disease, unstable courses, or discomfort with quantitative tracking.

4 Symptom Management for Mild-Moderate Cases

4.1 Cognitive Dysfunction (Brain Fog)

Rationale Cognitive dysfunction results from multiple mechanisms: catecholamine deficiency (Section Catecholamine Metabolism: NIH Study Findings), cerebral hypoperfusion (Section Cerebral Blood Flow Abnormalities), and reduced ATP availability in the brain (Section energy chain overview). Targeting neurotransmitter precursors and optimizing cerebral blood flow can improve function.

Non-Pharmaceutical

Cognitive pacing:
- Work in 25-minute blocks (Pomodoro technique), then 10-minute rest
- Schedule cognitively demanding tasks for peak energy times (usually morning)
- Minimize multitasking (switching costs energy)
- Reduce decision-making load (meal planning, outfit planning in advance)
Environmental optimization:
- Reduce sensory overload (quiet workspace, minimal visual clutter)
- Close unnecessary browser tabs/apps
- Use noise-canceling headphones if sound-sensitive

Pharmaceutical/Supplement

Tier 1 (try first):
- Caffeine + L-theanine (100 mg + 200 mg, 1–2 times daily)
- Alpha-GPC 300 mg BID (choline support for acetylcholine)
- Rhodiola rosea 200–400 mg morning (adaptogen, focus)
Tier 2 (add if Tier 1 helps):
- Bacopa monnieri 300 mg daily (memory consolidation)
- Lion’s Mane mushroom 500–1000 mg BID (nerve growth factor)
- Citicoline 250 mg BID (neuroprotection)
Tier 3 (prescription if severe cognitive impairment):
- Modafinil 50–100 mg morning (wakefulness, often prescribed off-label)
- Or: Methylphenidate 5 mg BID (stimulant, use cautiously)

Intranasal Delivery Routes for CNS-Targeted Compounds

Key Point: BBB Penetration and Intranasal Delivery

The blood-brain barrier (BBB) may limit delivery of compounds needed for cognitive support in ME/CFS (Hypothesis BBB Compartmentalization). Intranasal delivery bypasses the BBB via olfactory and trigeminal nerve pathways, achieving 2–10 fold higher CSF concentrations than oral routes.

Recommendation: Prioritizing Intranasal Routes When Available

For mild-moderate patients with prominent cognitive dysfunction:

Modafinil intranasal: If oral modafinil provides partial benefit, discuss intranasal formulations with prescribing physician. Not yet standard care but literature supports improved cognitive outcomes in other neurological conditions.
Dopamine or L-DOPA analogues (intranasal): Specialist neurologists may consider intranasal dopamine precursors if oral neurotransmitter support insufficient. EXPERIMENTAL; not standard ME/CFS care.
Future compounds: As understanding of the astrocyte energy gate hypothesis (Speculation Astrocyte Energy Gate) improves, intranasal delivery of lactate, ketone bodies, or neuroprotective compounds may emerge as targeted interventions.

Practical application: If cognitive symptoms dominate despite Tier 1–2 oral support, ask your physician about intranasal formulation options or referral to a neurologist familiar with BBB dysfunction.

Evidence level: Speculative (established for other neurological conditions; no ME/CFS-specific trials)

Transcranial Direct Current Stimulation (tDCS) for Cognitive Enhancement

Speculation: tDCS Energy Cost Reduction via DLPFC Modulation

Certainty: 0.25. Anodal tDCS targeting the DLPFC modulates cortical excitability and has demonstrated improvements in working memory, attention, and executive function in multiple studies (Q. Li et al. 2022). Applied to ME/CFS, this neural efficiency gain may reduce the energy cost of Tier 5 cognitive tasks (Section Selective Energy Dysfunction Hypothesis), thereby improving sustainable cognitive performance within the patient’s energy envelope. No ME/CFS-specific trials exist; the application to energy triage theory is speculative extrapolation.

Recommendation: Home tDCS Protocol for Cognitive Enhancement in Mild-Moderate ME/CFS

Mechanism: Anodal tDCS to DLPFC increases cortical excitability, potentially reducing energy cost of executive function through improved neural efficiency.

Protocol (home-based):

Equipment:
- tDCS device: Commercial home units (Thync, Flow, Halo Sport) or medical-grade devices ($300–2000)
- Budget option: DIY kits available but require strict safety adherence; medical supervision recommended initially
Stimulation parameters:
- Intensity: 2 mA (safe range for home use: 1–2 mA)
- Duration: 20 minutes daily
- Montage: F3-F4 (DLPFC bilateral, using 10-20 EEG positioning)
  - Anode (positive): F3 (left DLPFC)
  - Cathode (negative): F4 (right DLPFC) or right supraorbital
- Frequency: Daily or 5 days/week
- Duration of trial: 4–8 weeks to assess efficacy
Cognitive tracking during trial:
- Rate executive function daily (0–10 scale): Planning, multitasking, decision-making
- Track fatigue timing and intensity
- Monitor for mood or behavioral changes
- Weekly summary: “Week 1: no change. Week 3: Planning tasks feel 30% easier. Week 6: Sustained improvement in attention span.”
Safety considerations:
- Start with 1 mA if new to tDCS; escalate to 2 mA if well-tolerated
- Common side effects (mild, temporary): Tingling under electrodes, mild headache, slight skin redness
- Discontinue if: Persistent headache, mood changes, seizure activity
- Absolute contraindications: Metal implants in head/brain, history of seizures, pregnancy (insufficient safety data)
Integration with pacing:
- tDCS improves cognitive capacity but does NOT increase energy envelope
- Improved cognitive function may tempt increased activity; maintain strict pacing to avoid PEM
- Think: “More efficient cognition at same energy expenditure,” not “more capacity”

Evidence level: Speculative (tDCS efficacy for cognition documented; tDCS + energy triage model untested in ME/CFS)

Expected outcomes: 20–40% subjective improvement in executive function (planning, multitasking, decision-making). Effects may take 3–4 weeks to emerge. Not expected to improve fatigue directly; improves cognitive performance within existing energy envelope.

Practical consideration: Requires initial physician consultation for safety screening and proper electrode placement. Some occupational therapists experienced with tDCS can assist with home setup.

4.2 Sleep Dysfunction

Rationale Non-restorative sleep is a core ME/CFS symptom (Section Unrefreshing Sleep). Sleep dysfunction amplifies all other symptoms through effects on immune function (Section Immune Activation and Inflammation), pain sensitization, and cognitive impairment. Optimizing sleep is foundational to symptom control.

Sleep Hygiene (Non-Negotiable Foundation)

Same sleep/wake time every day (weekends included)
7–9 hour sleep opportunity (in bed, dark, quiet)
Room: 65–68°F, completely dark, quiet
No screens 2 hours before bed (or blue blockers)
No caffeine after 2pm
No large meals 3 hours before bed
Wind-down routine: 30 minutes relaxing activity before bed (reading, gentle stretching, meditation)

Supplements (Mild Cases Can Start Here)

Melatonin 0.3–0.5 mg (2 hours before target sleep time; low dose preserves sleep architecture)
Magnesium glycinate 400 mg evening - NOTE: At upper end of RDA (320 mg women, 420 mg men). Provides 400 mg elemental magnesium for muscle relaxation and calming. Very safe, well-tolerated. May cause loose stools if exceed tolerance (reduce dose if occurs).
L-theanine 200 mg before bed (anxiolytic)
Glycine 3 g before bed - NOTE: Exceeds typical supplement dose (1–2 g) by 1.5–3$\\times$. Clinical studies for sleep quality improvement use 3 g (Inagawa et al. 2006). Mechanism: Glycine lowers core body temperature via NMDA receptor agonism in the suprachiasmatic nucleus, facilitating sleep onset (Bannai and Kawai 2012). Extremely safe (used as food additive); no adverse effects in clinical trials. Sweet taste can be mixed in water.

Prescription (If Supplements Insufficient)

Trazodone 25–50 mg (lower dose than severe cases; increase if needed)
Mirtazapine 7.5 mg (also helps appetite)
Doxepin 3–6 mg (low-dose, histamine antagonist, improves sleep maintenance)

Dual Orexin Receptor Antagonists (DORAs) for Chronic Sleep Support

Achievement: Daridorexant: Evidence-Based DORA for ME/CFS Sleep

Dual orexin receptor antagonists (DORAs) offer a mechanistically targeted approach to ME/CFS sleep dysfunction, given documented orexin system abnormalities in the condition (López-Amador 2025). Daridorexant (Quviviq), FDA-approved in 2022, has robust evidence from multiple meta-analyses: Rocha et al. (Rocha et al. 2023) (10 RCTs, n=7,806) established dose-response relationships; Xue et al. (Xue et al. 2022) (13 RCTs) confirmed class-wide DORA efficacy; Dutta et al. (Dutta et al. 2023) provided GRADE assessment showing MODERATE certainty for safety comparable to placebo.

Unlike Z-drugs and benzodiazepines, DORAs consolidate sleep by reducing long wake bouts (>6 minutes) correlated with daytime impairment, while preserving brief arousals that maintain healthy sleep-wake boundary control (DiMarco et al. 2023). This mechanism addresses non-restorative sleep without producing hangover effects or tolerance.

Long-term safety: 52-week extension study (n=801) demonstrated no tolerance or withdrawal phenomena with continuous or intermittent use (Kunz et al. 2022).

Practical protocol: Start daridorexant 25 mg 30 minutes before bedtime with at least 7 hours available for sleep (Nie and Blair 2023). If insufficient after 4–6 weeks, increase to 50 mg. Safe for chronic use without tolerance development (St Onge, Phillips, and Rowe 2022). Advantages over traditional sleep aids: No next-day sedation; no cognitive impairment; no tolerance; suitable for long-term use in ME/CFS.

Limitations: No ME/CFS-specific RCTs exist. Prescription required; cost may be barrier. Alternative DORAs (suvorexant, lemborexant) have similar efficacy if daridorexant unavailable.

Emerging mechanistic note (certainty 0.25): Preclinical evidence suggests DORAs may have neuroprotective effects beyond sleep promotion. Parhizkar et al. (2025) demonstrated that lemborexant reduces tau phosphorylation via PKA pathway inhibition, preserving hippocampal volume by 30–40% in tauopathy mice (Parhizkar et al. 2025), while the Z-drug zolpidem increased sleep but provided no protection. Lucey et al. (2023) showed acute suvorexant reduced CSF p-tau181 by ~10–15% in cognitively unimpaired adults (Lucey et al. 2023). Whether DORAs provide any neuroprotection in ME/CFS (where tau pathology is unestablished) or whether partial endogenous orexin deficiency already confers this protection is unknown. These findings do not change the clinical recommendation above; they reinforce the mechanistic distinction between DORAs and GABA-A hypnotics.

Circadian Light Therapy for Sleep-Energy Alignment

Key Point: Circadian Energy Misallocation in ME/CFS

The selective energy dysfunction hypothesis (Hypothesis Circadian Misallocation of Energy Budget) proposes that SCN dysfunction impairs circadian allocation of energy budgets, explaining why many patients experience energy crashes mid-afternoon but a late-evening “second wind.”

Recommendation: Circadian Light Therapy: Entrainment Protocol

Mechanism: Bright morning light exposure resets the circadian oscillator, improving alignment between energy availability and day-night cycle. This synergizes with sleep medications by improving melatonin timing.

Protocol (same as severe cases):

Equipment: 10,000 lux light therapy box ($25–100)
Timing: Within 30 minutes of waking, 20–30 minutes daily, same time every day
Position: 16–24 inches from face, 30° downward angle
Do NOT use after 3pm (risk of sleep disruption)

Evidence level: Moderate (circadian disruption documented; light therapy established for circadian disorders; ME/CFS-circadian-energy RCTs pending)

Expected outcomes:

More consistent daytime energy
Earlier, easier sleep onset at night
Reduced afternoon crashes
Timeline: 2–4 weeks

Sleep Spindle Enhancement via Acoustic Stimulation (Low Priority, Optional)

Recommendation: Pink/White Noise for Sleep Architecture Improvement

Mechanism: Sleep spindles (brief high-frequency brain activity during NREM sleep) are reduced in ME/CFS. Acoustic stimulation may enhance spindle production, potentially improving sleep restorativeness (Hypothesis Sleep Architecture CNS Coordination Failure).

Simple, Low-Cost Protocol:

Equipment: White or pink noise machine ($10–50) or free app (myNoise.net, Noisli)
- White noise: Constant across frequencies; easier to find and more common
- Pink noise: Lower frequencies emphasized; some literature suggests superior sleep effects
How to use:
- Play throughout entire sleep period
- Volume: Low (30–50 dB, about conversational level)
- Placement: Bedside speaker or sleep-friendly earplugs
Trial duration: 2–4 weeks minimum to assess effect
Tracking:
- Subjective sleep quality rating (0–10)
- Morning refreshedness
- Daytime cognitive clarity
- Expected timeline: 2–4 weeks if beneficial

Evidence level: Speculative (spindle deficits documented in ME/CFS; acoustic enhancement effect unproven in this population)

Expected outcomes: Modest improvement in sleep quality perception. Not expected to directly improve daytime fatigue.

Positioning: Low-priority addition. Sleep medications (melatonin, trazodone) have stronger evidence. Use acoustic stimulation if medications insufficient or patient prefers non-pharmacological approach.

4.3 Pain

Rationale Pain in ME/CFS involves inflammatory mediators (Section Cytokines and Inflammatory Mediators), small fiber neuropathy (Section Peripheral Nervous System), and central sensitization. Addressing inflammation and neuropathic pathways reduces pain burden.

Mild-Moderate Pain Management

First-line:
- Ibuprofen 400 mg PRN or BID (with food)
- Or: Naproxen 220–500 mg BID
- Topical: Diclofenac gel (Voltaren) to painful areas
Add if insufficient:
- Low-dose naltrexone (LDN) 1.5–4.5 mg nightly (immune modulation + pain)
- Turmeric/curcumin 500–1000 mg BID (natural anti-inflammatory)
- Magnesium glycinate 400 mg daily (muscle relaxation)
Neuropathic pain component:
- Gabapentin 100 mg at bedtime, increase slowly to 300–600 mg BID if needed
- Or: Duloxetine 30–60 mg daily (also helps mood)

Palmitoylethanolamide (PEA) for Neuropathic and Inflammatory Pain

Palmitoylethanolamide (PEA) meta-analytic evidence for chronic pain reduction.
Meta-Analysis	Key Findings
Artukoglu et al. (Artukoglu et al. 2017)	10 studies (n=1298); weighted mean difference 2.03 (95% CI 1.19–2.87, $p < 0.001$)
Lang-Ilievich et al. (Lang and Ilievich 2023)	11 double-blind RCTs (n=774); SMD 1.68 (95% CI 1.05–2.31, $p < 0.00001$)
Viña, López-Moreno (Viña et al. 2025)	18 RCTs (n=1196); nociceptive SMD=-0.74, neuropathic SMD=-0.97, nociplastic SMD=-0.59

Evidence quality: HIGH for general chronic pain (multiple independent meta-analyses, n>1000 patients). MEDIUM for ME/CFS-specific use (extrapolated; no ME/CFS RCTs).

Hypothesis: PEA Mechanisms Align with ME/CFS Pain Pathophysiology

Certainty: 0.45. PEA’s mechanisms of action directly target pathways implicated in ME/CFS pain. Petrosino et al. (Petrosino et al. 2019) demonstrated that PEA counteracts mast cell activation by stimulating diacylglycerol lipase-$\beta$ (DAGL-$\beta$), increasing endogenous 2-arachidonoylglycerol (2-AG), which activates CB2 receptors to inhibit mast cell degranulation and histamine release—particularly relevant given mast cell activation in ME/CFS subsets (Section tVNS Caution in Severe ME/CFS). Additionally, PEA functions as a PPAR-$\alpha$ agonist, reducing neuroinflammation through glial cell modulation and suppression of pro-inflammatory cytokine expression (Varrassi et al. 2025).

Falsifiable prediction: ME/CFS patients with prominent pain and MCAS features receiving micronized PEA 600 mg BID will show ≥30% reduction in pain scores (VAS) at 12 weeks compared to placebo, with measurable reduction in serum mast cell mediators (tryptase, histamine).

Practical protocol: Prefer micronized or ultramicronized PEA formulations (enhanced solubility profile; superiority over standard PEA on clinical outcomes remains under investigation (Lang-Illievich et al. 2023)). Dose: 600 mg twice daily. Time to benefit: 4–6 weeks for initial effect; peak benefit at 24–26 weeks (Lang-Illievich et al. 2023). Excellent safety profile with minimal side effects documented across trials.

Positioning: Consider in the “Add if insufficient” tier alongside LDN and curcumin. PEA has a larger evidence base than curcumin (multiple meta-analyses (Lang-Illievich et al. 2023) vs limited RCT data). Particularly indicated if: mast cell activation features present, neuropathic pain component inadequately controlled, or inadequate NSAID response.

4.4 Orthostatic Intolerance (POTS)

Rationale Orthostatic intolerance affects 70–90% of ME/CFS patients (Section Autonomic Nervous System Dysfunction). Reduced blood volume (Section blood volume), autonomic dysfunction (Section Autonomic Nervous System Dysfunction), and impaired vascular regulation contribute. Blood volume expansion and compression improve tolerance.

Mild-Moderate Interventions

Compression: Waist-high stockings 20–30 mmHg (lower compression than severe cases)
Salt: 6–8 g sodium daily - NOTE - DRAMATICALLY EXCEEDS STANDARD RECOMMENDATION: Standard guideline is $\\<$ 2300 mg (2.3 g) daily. We recommend 6000–8000 mg (6–8 g) sodium daily, which is 2.6–3.5$\\times$ standard. See Chapter Urgent Action Plan for Severe Cases for complete justification (blood volume expansion for orthostatic intolerance, standard POTS treatment). Electrolyte drinks make compliance easier. CONTRAINDICATIONS: Hypertension, heart failure, kidney disease. Monitor BP weekly.
Oral rehydration solution (ORS) - dual benefit: Beyond simple blood volume expansion, properly formulated electrolyte solutions address the chronic metabolic stress state documented in Section Catecholamine Metabolism: NIH Study Findings. ME/CFS patients exist in a continuous state of lactate accumulation and reliance on anaerobic metabolism similar to post-exercise metabolic stress in athletes (see Chapter Energy Metabolism and Mitochondrial Function). Strategic electrolyte replacement serves multiple purposes:
- Blood volume expansion: Maintains preload for cardiac output; reduces orthostatic intolerance
- Lactate clearance: Helps clear accumulated lactic acid from impaired oxidative metabolism
- Glucose availability: Provides immediate energy when fat-burning is impaired
- Electrolyte balance: Supports muscle function and reduces cramping from ATP depletion

Recommended formulation (sports medicine-derived):

- Dry mix: 100 g sugar + 15 g low-sodium salt (KCl) + 15 g table salt (NaCl)
- Dosing: 7 g dry mix in 250 mL water, twice daily
- Flavoring optional (e.g., 10 mL grenadine for palatability)
- Cost: $\\<$€5 for months of supply

This formulation provides sodium, potassium, chloride, and glucose in ratios optimized for absorption and metabolic support. See the “Success Story: Sports Medicine and ME/CFS” section in Chapter Integrative and Personalized Treatment Approaches for the clinical insight that led to this protocol development.

Fluids: 2.5–3 L daily
Positional changes: Rise slowly (sit 30 seconds before standing)
Counter-maneuvers: Leg crossing, muscle tensing when standing
Exercise: Recumbent bike or rowing (horizontal position) within energy envelope

Compression Garments for Autonomic Load Reduction

Recommendation: Medical-Grade Compression Stockings for Mild-Moderate Orthostatic Intolerance

Mechanism: Compression garments reduce autonomic coordination load by maintaining peripheral venous pressure, reducing baroreceptor-mediated sympathetic activation required for orthostatic compensation (Speculation SFN Increases CNS Coordination Load: SFN interface failure).

Practical Protocol:

Compression class selection:
- Class II (20–30 mmHg): Recommended for mild-moderate orthostatic intolerance
- Waist-high or thigh-high: Covers leg venous return (most effective for OI)
- Material: Medical-grade merino wool or synthetic (avoid cotton which loses compression)
Wearing schedule:
- During upright activities: All times patient is sitting or standing (except during sleep or recumbent rest)
- Examples: Work day, meals, therapy appointments, activities
- Remove during sleep: Not needed in horizontal position
- Daily wear: 8–12 hours typical
Expected benefits:
- Reduced tachycardia with position changes
- Improved cognitive clarity (cerebral perfusion stabilized)
- Reduced fatigue from sustained orthostatic compensation
- Better work/school tolerance and attendance
Practical considerations:
- Fitting: Measure leg diameter for proper sizing; incorrect fit loses effectiveness
- Compliance: Some patients may resist wearing; emphasize improved energy/cognition benefits
- Cost: Medical-grade stockings $30–60 per pair; insurance may cover with prescription for POTS
- Longevity: Replace every 3–6 months (lose compression with washing)
Integration with other OI treatments:
- Combine with salt loading and hydration protocol for maximum effect
- Can be used with medications (midodrine, fludrocortisone)
- Adjunctive benefit; should not replace blood volume expansion

Evidence level: Moderate (20–30 mmHg compression established for POTS; extends to autonomic-primary ME/CFS subtype with SFN features)

Expected outcomes: 20–40% reduction in orthostatic symptoms when combined with salt/fluid protocol. Effects may take 1–2 weeks as patient adjusts to compression.

Prescription (If Above Insufficient)

Fludrocortisone 0.05–0.1 mg daily (increases blood volume)
Midodrine 2.5–10 mg TID (peripheral vasoconstrictor)
Beta-blockers (propranolol, metoprolol) - use cautiously, can worsen fatigue in some
Ivabradine 2.5–7.5 mg BID (If blocker) - Selectively reduces heart rate by inhibiting the I_f current in sinoatrial node. Advantages over beta-blockers: Does not reduce contractility or blood pressure; may be better tolerated in ME/CFS patients prone to hypotension. More commonly used in Europe than US. Patient reports indicate significant functional improvement (e.g., standing HR reduction from 150 to 90+ bpm). Contraindications: Bradycardia (HR $<$ 60), hypotension, sick sinus syndrome, concurrent use with strong CYP3A4 inhibitors.

4.5 Neuromodulation: Transcutaneous Vagus Nerve Stimulation (tVNS)

Achievement: tVNS Reduces Orthostatic Tachycardia in POTS

Teixeira et al. (Teixeira et al. 2024) conducted the first randomized, double-blind, sham-controlled trial of transcutaneous vagus nerve stimulation (tVNS) for postural tachycardia syndrome. Daily tragus stimulation (20 Hz, 1 mA below discomfort threshold, 1 hour per day for 2 months, n=26) significantly reduced orthostatic tachycardia compared to sham (heart rate increase during tilt test: 26.4 bpm at baseline $\to$ 17.6 bpm at 2 months in active group, p<0.05; no change in sham group).

Mechanisms included decreased $\beta_1$-adrenergic and $\alpha_1$-adrenergic receptor autoantibodies, reduced inflammatory cytokines, and improved heart rate variability. The intervention was well-tolerated with no serious adverse events (Farmer et al. 2022).

Study quality: MODERATE (single randomized, sham-controlled trial, n=26; requires larger replication trials before confidence is high). Single-site, small sample, and exclusion of complex comorbidities limit generalisability.

Practical protocol: Auricular tVNS targeting tragus or cymba concha; 20–25 Hz, 0.5–1 mA (below discomfort threshold); start with 5–10 minutes daily and gradually increase to 30–60 minutes over several weeks. Devices include FDA-approved GammaCore (cervical) and research/CE-marked auricular devices (NEMOS, Parasym). Home-based treatment suitable for bedbound patients.

Expected outcomes and timeline:

Primary (POTS, evidence level HIGH): Reduction in orthostatic tachycardia of 8–10 bpm on tilt test at 2 months of daily 1-hour stimulation, documented in the Teixeira 2024 sham-controlled RCT (n=26) (Teixeira et al. 2024). No additional improvement beyond 2 months was assessed in the trial.
Secondary (autonomic): Improved HRV (RMSSD increase, LF/HF ratio decrease) detectable within 2–4 weeks. Subjective reduction in palpitations and orthostatic presyncope may be apparent within 1–2 weeks.
Tertiary (immunomodulatory, uncertain): Reduced pro-inflammatory cytokines via cholinergic anti-inflammatory pathway — detectable at 4 weeks per SPM induction protocol (TUDCA and 4-Phenylbutyrate for ER Stress/UPR Inhibition). SPM elevation plates at 8 weeks.
Tertiary (vagal tone conditioning, uncertain): Sustained improvement in resting HRV after 8–12 weeks of consistent daily use, suggesting long-term neuroplasticity of vagal efferent pathways. Unproven — derived from tVNS epilepsy and depression literature; not tested in POTS or ME/CFS.
Time to no-effect decision: If no subjective benefit (palpitations, orthostatic tolerance, sleep quality) is perceived after 8 weeks of consistent use at the target dose, the intervention may be discontinued — the tVNS evidence base does not support benefit beyond 8 weeks if no early signal is present.

Warning: tVNS Caution in Severe ME/CFS

An international ME/CFS patient survey (n=116) found that “normal” tVNS settings can cause crashes in severe ME/CFS patients (Lugg et al. 2024), although 56% reported favorable effects overall. For severe ME/CFS: use very gradual titration (start 0.5 mA, 5 minutes), monitor for delayed symptom exacerbation (24–48 hours), and discontinue if crashes occur. Formal trials to identify safe parameters for the ME/CFS population are needed.

5 Mast Cell Activation Syndrome (MCAS) Management

5.1 Evidence and Rationale

Mast cell activation affects 30–50% of ME/CFS patients (Wirth and Scheibenbogen 2023). Recent research demonstrates measurable mast cell phenotype abnormalities with significant increases in naïve mast cells and elevated activation markers (Hardcastle et al. 2016). MCAS may worsen orthostatic intolerance, brain fog, and fatigue through excessive histamine and vasoactive mediator release (Wirth and Scheibenbogen 2023).

Critical finding: H1 antihistamine alone showed NO benefit in double-blind RCT (Steinberg et al. 1996). However, H1+H2 combination showed dramatic improvement in Long COVID case meeting ME/CFS criteria, with symptom worsening upon discontinuation (Davis et al. 2023).

5.2 Trial Indications

Consider MCAS trial if ANY present:

Food sensitivities/intolerances (especially new-onset)
Documented allergies (elevated IgE to foods, pollens, environmental allergens)
Flushing, hives, itching
Reactive to fragrances, chemicals
GI symptoms (post-meal nausea, bloating)
Unexplained anxiety/panic-like episodes
Fluctuating brain fog (worse after eating or exposure to triggers)

5.3 Treatment Options (Evidence-Based Hierarchy)

Option 1: Standard H1+H2 Combination Based on Long COVID case evidence (Davis et al. 2023):

H1: Loratadine 10 mg OR fexofenadine 180 mg (morning)
H2: Famotidine 20 mg twice daily
Expected benefits: Energy, cognitive function, orthostatic tolerance

Option 2: Rupatadine (Superior H1 Choice) Rupatadine offers unique advantages Piñero-González et al. (2017; Mullol et al. 2008):

Triple mechanism: H1 antagonist + PAF antagonist + mast cell stabilizer
Superior efficacy: Network meta-analysis ranks rupatadine 20 mg highest (SUCRA 99.7%) vs loratadine (lowest rank) (Mullol et al. 2008)
PAF antagonism: 31$\\times$ more potent than loratadine at blocking PAF; addresses vascular dysfunction in ME/CFS Piñero-González et al. (2017)
Mast cell stabilization: Inhibits IL-8 (80%), VEGF (73%), histamine (88%) Piñero-González et al. (2017)

Recommended protocol:

Rupatadine 10 mg morning (increase to 20 mg after 1–2 weeks if insufficient benefit)
Add famotidine 20 mg BID for complete histamine receptor coverage
Optional: Add quercetin 500–1000 mg daily (see below)

Option 3: Quercetin (Natural Mast Cell Stabilizer) Evidence shows quercetin MORE effective than prescription cromolyn (Theoharides, Asadi, and Panagiotidou 2012):

Dose: 500–1000 mg daily (clinical trials used up to 2 g/day)
Evidence: Reduced contact dermatitis reactions $>$ 50% in 8 of 10 patients; outperformed cromolyn for substance P-induced mast cell activation (Theoharides, Asadi, and Panagiotidou 2012)
Advantages: Over-the-counter, well-tolerated, additional antioxidant benefits
Can combine with H1+H2 antihistamines for comprehensive mast cell targeting

5.4 4-Week Trial Protocol

Week 1–2: Start H1 antihistamine

Rupatadine 10 mg morning (preferred), OR
Fexofenadine 180 mg OR loratadine 10 mg morning
Monitor for sedation (rare with rupatadine/fexofenadine)

Week 2–4: Add H2 blocker

Famotidine 20 mg twice daily (morning and evening)
Note: May reduce stomach acid; take iron supplements 2 hours apart

Optional Enhancement:

Add quercetin 500–1000 mg daily for additional mast cell stabilization

Low-histamine diet (adjunct):

Avoid: Aged/fermented foods, alcohol, cured meats, leftovers $>$ 24 hours
Duration: Strict 2-week trial, then gradual reintroduction

Assessment at Week 4:

Discontinuation test: Stop antihistamines for 2–3 days
If symptoms worsen $\to$ mast cell component confirmed $\to$ continue therapy
If no change $\to$ discontinue (not MCAS-driven)

Expected Response

May improve (if MCAS-related):

Brain fog and cognitive clarity
Energy levels (especially post-meal fatigue)
GI symptoms (bloating, nausea, diarrhea)
Orthostatic tolerance
Flushing and allergic symptoms
Anxiety/panic-like episodes

Will NOT improve (metabolic/mitochondrial):

Core fatigue (“running on empty”) — requires mitochondrial support
Muscle cramps — requires carnitine, magnesium
PEM from overexertion — requires pacing
Progressive vision/hearing loss — different mechanisms

Special Note: Amitriptyline for Dual Benefit

If pain and/or sleep issues coexist with MCAS features, amitriptyline provides dual benefit (Clemons et al. 2011):

Dose: 10–50 mg at bedtime
Mechanisms: Mast cell inhibition (reduces IL-8, VEGF, IL-6, histamine) (Clemons et al. 2011) + pain relief + sleep improvement
Specificity: This mast cell effect is unique to amitriptyline; other antidepressants (bupropion, citalopram, atomoxetine) do NOT inhibit mast cells (Clemons et al. 2011)
Genetic signal: The DecodeME GWAS found $r_g = 0.61$ between ME/CFS and amitriptyline use—comparable to the depression correlation ($r_g = 0.60$). This may reflect more than confounding: amitriptyline’s NMDA antagonism targets the same glutamatergic circuits identified at DecodeME genome-wide significant loci (SHISA6, UNC13C). Low-dose amitriptyline may thus act on genetically-identified neural substrates in ME/CFS, not merely palliate symptoms (Speculation Integrative Speculations, Chapter Integrative Models and Multi-System Pathophysiology) (ME/CFS Science 2025)
Can combine with rupatadine + famotidine for comprehensive mast cell targeting

MCAS Prophylactic Intensification for High-Demand Activities and Known Triggers

Recommendation: Prophylactic Intensification for Mild-Moderate MCAS Patients

Mechanism: Mast cell activation episodes amplify fatigue and cognitive crashes through inflammatory mediators (Hypothesis Mast Cell Activation Amplifies CNS Energy Deficit). Proactive medication intensification 1–2 days before high-demand activities can reduce crash severity.

Protocol (adapted for mild-moderate severity):

Identify your triggers (2–4 weeks baseline tracking):
- Activities: Exercise, busy work/school days, emotional stress
- Foods: Histamine-rich (aged cheese, fermented foods, red wine, cured meats)
- Environmental: Heat, cold, strong fragrances, weather changes
- Immune: Infections, vaccinations, allergy exposure
Prophylactic medication protocol (BEGIN 24 HOURS BEFORE known triggers):
- Increase antihistamine dosing:
  - If on rupatadine 10 mg: Increase to 20 mg daily during trigger window (if previously well-tolerated)
  - If on loratadine/fexofenadine: May increase frequency but dose caps apply (consult pharmacist)
  - Famotidine: Increase to 40 mg BID (maximum therapeutic dose) during trigger window
- Add mast cell stabilizer if not already taking:
  - Quercetin 1000 mg BID (1–2 days pre-trigger and during)
  - Omega-3 PUFA 2–3 g daily (natural stabilizing effect)
- Strict low-histamine diet (absolute 24 hours before through 24 hours after trigger):
  - Eliminate all aged/fermented foods
  - Only fresh foods prepared same-day
  - Skip known personal food triggers
- Activity pacing intensification:
  - Reduce non-essential activities day-of trigger
  - Maintain strict heart rate pacing limits
  - Prioritize rest before and after high-demand event
Track crash response:
- Rate post-trigger crash severity (0–10 scale)
- WITH prophylaxis: “Normally crash 6/10 for 2 days; prophylaxis reduced to 3/10 for 1 day”
- WITHOUT prophylaxis: “Skipped prophylaxis, crashed 7/10 for 2.5 days”
- Adjust prophylaxis strategy based on efficacy pattern

Evidence level: Moderate (MCAS prophylaxis standard in allergology; ME/CFS crash-mitigation studies pending)

Expected outcomes: 25–50% reduction in crash severity or duration when MCAS component is substantial. Lesser benefit if non-MCAS mechanisms predominate.

References

Addleman, Jennifer S., Nicholas S. Lackey, Justin A. DeBlauw, and Alexander G. Hajduczok. 2024. “Heart Rate Variability Applications in Strength and Conditioning: A Narrative Review.” Journal of Functional Morphology and Kinesiology 9 (2): 93. https://doi.org/10.3390/jfmk9020093.

Artukoglu, B. et al. 2017. “Efficacy of Palmitoylethanolamide for Pain: Meta-Analysis of 10 Randomized Controlled Trials Involving 1,298 Patients.” Pain Physician 20 (5): 353–62.

Bannai, Makoto, and Nobuhiro Kawai. 2012. “New Therapeutic Strategy for Amino Acid Medicine: Glycine Improves the Quality of Sleep.” Journal of Pharmacological Sciences 118 (2): 145–48. https://doi.org/10.1254/jphs.11R04FM.

Bell, Lee, Ben W. Strafford, Milo Coleman, Patroklos Androulakis Korakakis, and Declan Nolan. 2023. “Integrating Deloading into Strength and Physique Sports Training Programmes: An International Delphi Consensus Approach.” Sports Medicine - Open 9 (1): 87. https://doi.org/10.1186/s40798-023-00633-0.

Clemons, Adam, Maria Vasiadi, Duraisamy Kempuraj, Theoharis Kourelis, George Vandoros, and Theoharis C Theoharides. 2011. “Amitriptyline and Prochlorperazine Inhibit Proinflammatory Mediator Release from Human Mast Cells: Possible Relevance to Chronic Fatigue Syndrome.” Journal of Clinical Psychopharmacology 31 (3): 385–87. https://doi.org/10.1097/JCP.0b013e3182196e50.

Davis, H. E., L. McCorkell, J. M. Vogel, and E. J. Topol. 2023. “Case Study of ME/CFS Care Applied to Long COVID: Hypothesis Regarding Exercise Intolerance, Orthostatic Intolerance, Mast Cell Activation, Sleep Dysfunction, Neuropathy, and Viral Persistence.” Healthcare 11 (6): 896. https://doi.org/10.3390/healthcare11060896.

DiMarco, M. et al. 2023. “Wake Bout Analysis: Daridorexant Consolidates Sleep Through Reduction of Long Wake Bouts Compared to Zolpidem.” CNS Drugs 37 (7): 639–53. https://doi.org/10.1007/s40263-023-01019-8.

Dutta, S. et al. 2023. “Daridorexant Safety Profile: A GRADE Systematic Review.” Expert Opinion on Drug Safety 22 (12): 1237–51. https://doi.org/10.1080/14740338.2023.2242877.

Eaton-Fitch, Natalie, Stanley du Preez, Hélène Cabanas, Donald Staines, and Sonya Marshall-Gradisnik. 2019. “A Systematic Review of Natural Killer Cells Profile and Cytotoxic Function in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.” Systematic Reviews 8: 279. https://doi.org/10.1186/s13643-019-1202-6.

Escorihuela, Rosa Maria, Lluis Capdevila, Jose R. Castro, M. Carmen Zaragozà, Sílvia Maurel, José Alegre, and Jesus Castro-Marrero. 2020. “Reduced Heart Rate Variability Predicts Fatigue Severity in Individuals with Chronic Fatigue Syndrome/Myalgic Encephalomyelitis.” Journal of Translational Medicine 18 (1): 4. https://doi.org/10.1186/s12967-019-02184-z.

Farmer, A. D. et al. 2022. “Transcutaneous Auricular Vagus Nerve Stimulation in Gastrointestinal and Functional Disorders: A Systematic Review and Meta-Analysis.” Scientific Reports 12: 21167. https://doi.org/10.1038/s41598-022-25864-1.

Hardcastle, Susan L, Ekua W Brenu, Samantha Johnston, Thao Nguyen, Teilah Huth, Maninder Kaur, Sandra B Ramos, et al. 2016. “Novel Characterisation of Mast Cell Phenotypes from Peripheral Blood Mononuclear Cells in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis Patients.” BMC Immunology 17 (1): Article 30. https://doi.org/10.1186/s12865-016-0167-z.

Heng, Ruiwen Benjamin, Bavani Gunasegaran, Shivani Krishnamurthy, Sonia Bustamante, Ananda Staats, Sharron Chow, Seong Beom Ahn, et al. 2025. “Mapping the Complexity of ME/CFS: Evidence for Abnormal Energy Metabolism, Altered Immune Profile, and Vascular Dysfunction.” Cell Reports Medicine 6 (12): 102514. https://doi.org/10.1016/j.xcrm.2025.102514.

Hooper, Sue L., and Laurel T. Mackinnon. 1995. “Monitoring Overtraining in Athletes: Recommendations.” Sports Medicine 20 (5): 321–27. https://doi.org/10.2165/00007256-199520050-00003.

Inagawa, K., T. Hiraoka, T. Kohda, W. Yamadera, and M. Takahashi. 2006. “Subjective Effects of Glycine Ingestion Before Bedtime on Sleep Quality.” Sleep and Biological Rhythms 4 (1): 75–77. https://doi.org/10.1111/j.1479-8425.2006.00193.x.

Keller, Betsy A, Candace N Receno, Carl J Franconi, Sebastian Harenberg, Jared Stevens, Xiangling Mao, Staci R Stevens, et al. 2024. “Cardiopulmonary and Metabolic Responses During a 2-Day CPET in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Translating Reduced Oxygen Consumption to Impairment Status to Treatment Considerations.” Journal of Translational Medicine 22 (1): 627. https://doi.org/10.1186/s12967-024-05410-5.

Kunz, D. et al. 2022. “52-Week Safety and Tolerability Extension of Daridorexant in Patients with Insomnia.” CNS Drugs 36 (12): 1303–15. https://doi.org/10.1007/s40263-022-00970-w.

Lang, S., and I. Ilievich. 2023. “Palmitoylethanolamide for Pain Relief: A Systematic Review of 11 Randomized Controlled Trials with 774 Participants.” Nutrients 15 (6): 1350. https://doi.org/10.3390/nu15061350.

Lang-Illievich, Kordula, Christoph Klivinyi, Christine Lasser, Christian T. A. Brenna, Istvan S. Szilagyi, Gudrun Rumpold-Seitlinger, Claudia Dorn, and Helmar Bornemann-Cimenti. 2023. “Palmitoylethanolamide in the Treatment of Chronic Pain: A Systematic Review and Meta-Analysis of Double-Blind Randomized Controlled Trials.” Nutrients 15 (6): 1350. https://doi.org/10.3390/nu15061350.

Lawless, Craig, Laura Greaves, Amy K Reeve, Douglass M Turnbull, and Amy E Vincent. 2015. “The Rise and Rise of Mitochondrial DNA Mutations.” Open Biology 5 (5): 150029. https://doi.org/10.1098/rsob.150029.

Li, Ke, Caroline Cardoso, Angelica Moctezuma-Ramirez, Ahmed Elgalad, and Emerson Perin. 2023. “Heart Rate Variability Measurement Through a Smart Wearable Device: Another Breakthrough for Personal Health Monitoring?” International Journal of Environmental Research and Public Health 20 (24): 7146. https://doi.org/10.3390/ijerph20247146.

Li, Qing, Yu Fu, Chang Liu, and Zhiqiang Meng. 2022. “Transcranial Direct Current Stimulation of the Dorsolateral Prefrontal Cortex for Treatment of Neuropsychiatric Disorders.” Frontiers in Behavioral Neuroscience 16: 893955. https://doi.org/10.3389/fnbeh.2022.893955.

López-Amador, Noé. 2025. “An Integrative Review on the Orexin System and Hypothalamic Dysfunction in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Implications for Precision Medicine.” Exploration of Neuroprotective Therapy 5: 1004112. https://doi.org/10.37349/ent.2025.1004112.

Lucey, Brendan P., Haiyan Liu, Cristina D. Toedebusch, David Freund, Tiara Redrick, Samir L. Chahin, Kwasi G. Mawuenyega, et al. 2023. “Suvorexant Acutely Decreases Tau Phosphorylation and a$\beta$ in the Human CNS.” Annals of Neurology 94 (1): 27–40. https://doi.org/10.1002/ana.26641.

Lugg, D. J. et al. 2024. “Transcutaneous Vagus Nerve Stimulation in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Patient Survey.” Fatigue: Biomedicine, Health & Behavior 12 (1). https://doi.org/10.1080/21641846.2023.2286029.

ME/CFS Science. 2025. “DecodeME: The Biggest ME/CFS Study Ever.” 2025. https://mecfsscience.org/decodeme-the-biggest-me-cfs-study-ever/.

Meeusen, Romain, Martine Duclos, Willem Brink, Laurent Bosquet, Véronique-Anne Bricout, Peter Hassmén, Andrew M. Jones, et al. 2013. “Prevention, Diagnosis, and Treatment of the Overtraining Syndrome: Joint Consensus Statement of the European College of Sport Science and the American College of Sports Medicine.” Medicine and Science in Sports and Exercise 45 (1): 186–205. https://doi.org/10.1249/MSS.0b013e318279a10a.

Mullol, Joaquim, Jean Bousquet, Claus Bachert, Walter G Canonica, Ana Gimenez-Arnau, Marek L Kowalski, Eulàlia Martí-Guadaño, et al. 2008. “Rupatadine in Allergic Rhinitis and Chronic Urticaria.” Allergy 63 (Suppl 87): 5–28. https://doi.org/10.1111/j.1398-9995.2008.01640.x.

Nakatomi, Yasuhito, Kei Mizuno, Akemi Ishii, Yasuhiro Wada, Masaaki Tanaka, Shusaku Tazawa, Kayo Onoe, et al. 2014. “Neuroinflammation in Patients with Chronic Fatigue Syndrome/Myalgic Encephalomyelitis: An ¹¹C-(R)-PK11195 PET Study.” Journal of Nuclear Medicine 55 (6): 945–50. https://doi.org/10.2967/jnumed.113.131045.

National Institute for Health and Care Excellence. 2021. “Myalgic Encephalomyelitis (or Encephalopathy)/Chronic Fatigue Syndrome: Diagnosis and Management.” NICE guideline [NG206]. https://www.nice.org.uk/guidance/ng206.

Nie, Tina, and Hannah A. Blair. 2023. “Daridorexant in Insomnia Disorder: A Profile of Its Use.” CNS Drugs 37 (3): 267–74. https://doi.org/10.1007/s40263-023-00987-9.

Parhizkar, Samira, Xin Bao, Wei Chen, Nicholas Rensing, Yusi Chen, Maia Kipnis, Sophie Song, et al. 2025. “Lemborexant Ameliorates Tau-Mediated Sleep Loss and Neurodegeneration in Males in a Mouse Model of Tauopathy.” Nature Neuroscience 28 (7): 1460–72. https://doi.org/10.1038/s41593-025-01966-7.

Petrosino, S. et al. 2019. “The Pharmacology of Palmitoylethanolamide and First Data on the Therapeutic Potential of a New Add-on Formulation in Fibromyalgia.” Journal of Neuroinflammation 16 (1): 238. https://doi.org/10.1186/s12974-019-1620-z.

Piñero-González, J, I Izquierdo, S Sánchez-García, and M F Martín-Muñoz. 2017. “Rupatadine Inhibits Proinflammatory Mediator Secretion from Human Mast Cells Triggered by Different Stimuli.” Journal of Investigational Allergology and Clinical Immunology 27 (3): 161–68. https://doi.org/10.18176/jiaci.0147.

Plews, Daniel J., Paul B. Laursen, Jamie Stanley, Andrew E. Kilding, and Martin Buchheit. 2013. “Training Adaptation and Heart Rate Variability in Elite Endurance Athletes: Opening the Door to Effective Monitoring.” Sports Medicine 43 (9): 773–81. https://doi.org/10.1007/s40279-013-0071-8.

Rocha, F. L. et al. 2023. “Dual Orexin Receptor Antagonists in Insomnia: Network Meta-Analysis of Dose-Response in 7,806 Patients.” Arquivos de Neuro-Psiquiatria 81 (5): 475–83. https://doi.org/10.1055/s-0043-1768659.

St Onge, Erin, Bradley Phillips, and Casey Rowe. 2022. “Daridorexant: A New Dual Orexin Receptor Antagonist for Insomnia.” Journal of Pharmacy Technology 38 (5): 297–303. https://doi.org/10.1177/87551225221112546.

Steinberg, Pearl, Brenda E McNutt, Paul Marshall, Carlos Schenck, Nancy Lurie, Ann Pheley, and Paul K Peterson. 1996. “A Double-Blind Placebo-Controlled Study of the Efficacy of Oral Terfenadine in the Chronic Fatigue Syndrome.” The Journal of Allergy and Clinical Immunology 97 (1 Pt 1): 119–26. https://doi.org/10.1016/S0091-6749(96)80212-6.

Teixeira, A. L. et al. 2024. “Tragus Stimulation in Postural Orthostatic Tachycardia Syndrome: First Sham-Controlled Randomized Trial.” JACC: Clinical Electrophysiology 10 (2): 264–75. https://doi.org/10.1016/j.jacep.2023.10.015.

Theoharides, Theoharis C, Shahrzad Asadi, and Sofia Panagiotidou. 2012. “Quercetin in Combination with IL-6 Inhibits Histamine and TNF Release from Mast Cells Through Interaction with the IL-6 Receptor.” PLOS ONE 7 (3): e33805. https://doi.org/10.1371/journal.pone.0033805.

Varrassi, G. et al. 2025. “Palmitoylethanolamide in Chronic Pain Conditions: 15 Years of Clinical Experience.” Pain and Therapy 14 (1): 37–57. https://doi.org/10.1007/s40122-024-00674-9.

Viña, J. et al. 2025. “Palmitoylethanolamide for Nociceptive, Neuropathic, and Nociplastic Pain: A Comprehensive Meta-Analysis of 18 Randomized Controlled Trials.” Nutrition Reviews, online ahead of print. https://doi.org/10.1093/nutrit/nuae146.

Wilshire, Carolyn E, Tom Kindlon, Robert Courtney, Alem Matthees, David Tuller, Keith Geraghty, and Bruce Levin. 2018. “Rethinking the Treatment of Chronic Fatigue Syndrome—a Reanalysis and Evaluation of Findings from a Recent Major Trial of Graded Exercise and CBT.” BMC Psychology 6 (1): 6. https://doi.org/10.1186/s40359-018-0218-3.

Wirth, Klaus, and Carmen Scheibenbogen. 2023. “Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Comorbidities: Linked by Vascular Pathomechanisms and Vasoactive Mediators?” Healthcare 11 (7): 978. https://doi.org/10.3390/healthcare11070978.

Xue, Y. et al. 2022. “Dual Orexin Receptor Antagonists for Insomnia: A Network Meta-Analysis of 13 Randomized Controlled Trials.” Sleep Medicine Reviews 61: 101573. https://doi.org/10.1016/j.smrv.2021.101573.